ValuEngine downgraded shares of LifePoint Health (NASDAQ:LPNT) from a sell rating to a strong sell rating in a research note published on Thursday.
Several other equities research analysts have also recently weighed in on the stock. Mizuho reissued a hold rating and set a $51.00 price target on shares of LifePoint Health in a research report on Thursday, March 22nd. Robert W. Baird reissued a buy rating and set a $54.00 price target on shares of LifePoint Health in a research report on Tuesday, March 27th. Wolfe Research raised shares of LifePoint Health from an underperform rating to a peer perform rating in a research report on Friday, March 16th. Royal Bank of Canada dropped their price target on shares of LifePoint Health to $58.00 and set an outperform rating for the company in a research report on Monday, February 26th. Finally, Morgan Stanley reissued an equal weight rating and set a $46.00 price target (down previously from $50.00) on shares of LifePoint Health in a research report on Monday, February 26th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $54.87.
Shares of LifePoint Health opened at $51.85 on Thursday, MarketBeat reports. LifePoint Health has a 52-week low of $41.45 and a 52-week high of $67.95. The firm has a market capitalization of $2.06 billion, a PE ratio of 14.28, a price-to-earnings-growth ratio of 1.36 and a beta of 0.51. The company has a debt-to-equity ratio of 1.28, a current ratio of 1.76 and a quick ratio of 1.55.
LifePoint Health (NASDAQ:LPNT) last announced its quarterly earnings data on Friday, May 4th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.13 by $0.09. LifePoint Health had a net margin of 0.48% and a return on equity of 6.56%. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.62 billion. During the same quarter in the prior year, the company earned $1.07 EPS. The firm’s revenue was down 1.7% on a year-over-year basis. equities research analysts forecast that LifePoint Health will post 4.3 EPS for the current year.
Large investors have recently bought and sold shares of the company. Point72 Asia Hong Kong Ltd lifted its position in shares of LifePoint Health by 1,897.5% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 2,417 shares of the company’s stock worth $114,000 after purchasing an additional 2,296 shares during the period. US Bancorp DE lifted its position in shares of LifePoint Health by 62.4% in the 4th quarter. US Bancorp DE now owns 3,095 shares of the company’s stock worth $155,000 after purchasing an additional 1,189 shares during the period. Xact Kapitalforvaltning AB purchased a new stake in shares of LifePoint Health in the 4th quarter worth about $230,000. Verition Fund Management LLC purchased a new stake in shares of LifePoint Health in the 1st quarter worth about $224,000. Finally, Alambic Investment Management L.P. purchased a new stake in shares of LifePoint Health in the 1st quarter worth about $240,000.
About LifePoint Health
LifePoint Health, Inc, through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers, and post-acute facilities in the United States. Its hospitals provide a range of medical and surgical services, such as general surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, rehabilitation, and pediatric, as well as specialized services, including open-heart surgery, skilled nursing, psychiatric care, and neuro-surgery.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for LifePoint Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifePoint Health and related companies with MarketBeat.com's FREE daily email newsletter.